awiqli flextouch
Pharmaranks rates Awiqli Flextouch 3.5/5 for recall safety — an independent score from its FDA recall history and its manufacturer's record. Awiqli Flextouch (Insulin Icodec) is a medication used to treat Type 2 Diabetes Mellitus.
Insulin Icodec · by Novo Nordisk Inc
Based on 1 source · Recall-safety score from FDA recall history — this product's own recalls and its manufacturer's record. Not an efficacy or quality rating. methodology →
Key facts
- Active ingredient
- Insulin Icodec
- Form
- Injectable
- Type
- Prescription (Rx)
- Brand or generic
- Brand-name
- May treat
- type 2 diabetes mellitus
- Manufacturer
- Novo Nordisk Inc
- FDA application
- BLA761326
May treat (source: NIH RxClass)
Dosage forms
Injectable
The forms currently marketed in the U.S., per the FDA National Drug Code Directory.
Ways to save
Ask for the generic
Same active ingredient, far cheaper. Is there a generic? →
Request a 90-day supply
Bulk fills usually lower the per-dose price vs monthly refills.
Use copay cards
Manufacturer copay cards & patient-assistance programs — especially for brand drugs.
Compare alternatives
A same-class option may cost less. See alternatives →
Frequently asked questions
- What does Awiqli Flextouch treat?
- Awiqli Flextouch (Insulin Icodec) may be used to treat type 2 diabetes mellitus, based on NIH RxClass drug-classification data (conditions a drug may treat — not a verbatim copy of the FDA-approved label). This is general reference, not medical advice.
- How is Awiqli Flextouch rated?
- pharmaranks gives Awiqli Flextouch a composite score of 3.5 out of 5, currently based on 1 weighted source (FDA regulatory recall-safety data weighted highest). See our methodology at /how-we-rate.
- Is there a coupon or discount for Awiqli Flextouch?
- pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Awiqli Flextouch. To pay less, ask your prescriber or pharmacist whether a generic equivalent exists, check the manufacturer's copay/savings card and patient-assistance program, and compare a pharmacy discount card against your insurance copay. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
- Who makes Awiqli Flextouch?
- Awiqli Flextouch is marketed by Novo Nordisk Inc. You can see Novo Nordisk Inc's full profile, rating, and other products on pharmaranks.
- Is Awiqli Flextouch a brand-name or generic drug?
- Awiqli Flextouch is a brand-name product with the active ingredient Insulin Icodec.
- Is Awiqli Flextouch available over the counter?
- No. Awiqli Flextouch is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
- What forms does Awiqli Flextouch come in?
- Awiqli Flextouch is currently marketed as injectable, per the FDA's National Drug Code Directory.
- Is Awiqli Flextouch FDA-registered?
- Awiqli Flextouch is on record with the U.S. FDA under application number BLA761326. You can verify this on its official FDA label.
- Has Awiqli Flextouch been recalled by the FDA?
- Awiqli Flextouch has no FDA recalls recorded under its own application in the openFDA enforcement database. Its recall-safety score reflects its manufacturer's overall recall record. This is general reference, not medical advice — check the FDA recall database for the latest alerts.
- Is Awiqli Flextouch safe?
- There's no single safe-or-not verdict. pharmaranks gives Awiqli Flextouch a recall-safety score of 70/100, based on its FDA recall history (no recalls under its own FDA application) — not an efficacy or side-effect rating. Review its FDA-label side effects and warnings before use, and always consult a licensed professional.
Information is sourced from public FDA regulatory data. Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.
What people report to the FDA about INSULIN ICODEC
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 57 reports naming INSULIN ICODEC — the active ingredient in Awiqli Flextouch, and the FDA flagged 98% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- hypoglycaemia21 reports
- fall4 reports
- hospitalisation4 reports
- hyperglycaemia4 reports
- blood glucose decreased3 reports
- blood glucose increased3 reports
- chronic kidney disease3 reports
- diarrhoea3 reports
Read these as a signal, not a rate. A report does not mean INSULIN ICODEC caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label.
Source: openFDA drug/event (FAERS), retrieved September 25, 2026.
Reviews
No reviews yet. Be the first to write one.
People also viewed
brynovin
Sitagliptin Hydrochloride
invokana
Canagliflozin
merilog
Insulin Aspart-Szjj
merilog solostar
Insulin Aspart-Szjj
rezvoglar
Insulin Glargine-Aglr
tradjenta
Linagliptin
Compare Awiqli Flextouch head-to-head
Browse medications A–Z
Research products from A to Z, compare independent ratings, and find alternatives.
awiqli flextouch
70/100